Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income
Beginning balance, value at Dec. 31, 2023	$ (6,905)	$ 0	$ 429,780	$ (436,684)	$ (1)
Beginning balance, shares at Dec. 31, 2023		4,423,683
Issuance of common stock, net of issuance costs, Value	180,237	$ 1	180,236
Issuance of common stock, net of issuance costs, Shares		7,462,916
Issuance of common stock upon cashless exercise of warrants		6,087
Issuance of common stock upon conversion of K2 Loan and Security Agreement, Shares		142,857
Issuance of common stock upon conversion of K2 Loan and Security Agreement, Value	1,125		1,125
Issuance of common stock upon exercise of stock options, Value	1,999		1,999
Issuance of common stock upon exercise of stock options, shares		136,664
Issuance of common stock upon vesting of restricted stock units, shares		7,275
Stock-based compensation expense	4,513		4,513
Change in unrealized gain (loss) on marketable debt securities	208				208
Net Income (Loss)	(30,679)			(30,679)
Ending balance, value at Sep. 30, 2024	150,498	$ 1	617,653	(467,363)	207
Ending balance, shares at Sep. 30, 2024		12,179,482
Beginning balance, value at Jun. 30, 2024	125,543	$ 1	579,510	(453,580)	(388)
Beginning balance, shares at Jun. 30, 2024		11,498,917
Issuance of common stock, net of issuance costs, Value	35,842	$ 0	35,842
Issuance of common stock, net of issuance costs, Shares		668,379
Issuance of common stock upon cashless exercise of warrants		6,087
Issuance of common stock upon exercise of stock options, Value	58		58
Issuance of common stock upon exercise of stock options, shares		2,588
Issuance of common stock upon vesting of restricted stock units, shares		3,511
Stock-based compensation expense	2,243		2,243
Change in unrealized gain (loss) on marketable debt securities	595				595
Net Income (Loss)	(13,783)			(13,783)
Ending balance, value at Sep. 30, 2024	150,498	$ 1	617,653	(467,363)	207
Ending balance, shares at Sep. 30, 2024		12,179,482
Beginning balance, value at Dec. 31, 2024	142,428	$ 1	619,285	(476,893)	35
Beginning balance, shares at Dec. 31, 2024		12,179,482
Issuance of common stock, net of issuance costs, Value	$ 2,880		2,880
Issuance of common stock, net of issuance costs, Shares		272,938
Issuance of common stock upon exercise of stock options, shares	0
Issuance of common stock upon vesting of restricted stock units, shares		82,433
Stock-based compensation expense	$ 4,859		4,859
Change in unrealized gain (loss) on marketable debt securities	(38)				(38)
Net Income (Loss)	(57,982)			(57,982)
Ending balance, value at Sep. 30, 2025	92,147	$ 1	627,024	(534,875)	(3)
Ending balance, shares at Sep. 30, 2025		12,534,853
Beginning balance, value at Jun. 30, 2025	110,991	$ 1	622,562	(511,533)	(39)
Beginning balance, shares at Jun. 30, 2025		12,254,069
Issuance of common stock, net of issuance costs, Value	2,880		2,880
Issuance of common stock, net of issuance costs, Shares		272,938
Issuance of common stock upon vesting of restricted stock units, shares		7,846
Stock-based compensation expense	1,582		1,582
Change in unrealized gain (loss) on marketable debt securities	36				36
Net Income (Loss)	(23,342)			(23,342)
Ending balance, value at Sep. 30, 2025	$ 92,147	$ 1	$ 627,024	$ (534,875)	$ (3)
Ending balance, shares at Sep. 30, 2025		12,534,853

Corbus Pharmaceuticals Holdings, Inc. 10-Q